Illumina CEO Says Next Round of GWAS Will Be Done on Arrays, Not Sequencers

While there is enthusiasm for the firm's sequencing instruments, Illumina believes arrays are currently "faster," "cheaper," and "more accurate" than existing next-generation sequencers for genome-wide association studies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.